Decision theoretic designs for phase II clinical trials with multiple outcomes, Nat Rev Drug Discov, vol.55, pp.27-36, 1989. ,
Sample sizes for phase II clinical trials derived from Bayesian decision theory, Stat Med, vol.13, pp.2493-502, 19945. ,
Decision-theoretic designs for phase II clinical trials allowing for competing studies, Biometrics, vol.59, pp.402-411, 20036. ,
Stopping rules for phase II studies, Br J Clin Pharmacol, vol.51, pp.523-532, 2001. ,
A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials, Control Clin Trials, vol.15, pp.463-81, 19948. ,
New statistical strategy for monitoring safety and efficacy in single-arm clinical trials, J Clin Oncol, vol.14, pp.296-303, 19969. ,
Handbook Of Beta Distribution And Its Applications, 200410. ,
Bayesian two-stage designs for phase II clinical trials, Stat Med, vol.21, 1991. ,
A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation, Stat Med, vol.12, p.15, 1993. ,
FDA FaDA: Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials -Draft Guidance for Industry and FDA Staff, Control Clin Trials, vol.25, p.17, 2004. ,
Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study, Br J Haematol, vol.119, pp.726-765, 200218. ,
The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies, Stat Med, vol.20, pp.2827-2870, 200119. ,
A Bayesian stopping rule for a single arm study: With a case study of stem cell transplantation, Stat Med, vol.25, pp.2956-66, 200620. ,
A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients, Berger JO: Statistical decision theory and Bayesian analysis, vol.18, pp.1518-1539, 1996. ,